Acute Coronary Syndrome

Detailed Overview

Acute Coronary Syndrome represents a medical emergency where time is muscle. In STEMI, a totally occlusive thrombus causes full-thickness (transmural) myocardial necrosis, necessitating immediate reperfusion via primary PCI or fibrinolytics. NSTEMI and UA involve a partially occlusive thrombus causing subendocardial ischemia; NSTEMI shows biomarker evidence of necrosis (elevated troponins), while UA does not. If left untreated, ACS leads to fatal arrhythmias, cardiogenic shock, or irreversible heart failure.

Epidemiology & Demographics

Incidence: >1 million hospital admissions for ACS annually in the US. Average age of first heart attack is 65.6 years for males and 72.0 years for females. Males have a higher incidence at younger ages, but the gap closes post-menopause.

Etiological Mechanism

The primary cause is coronary artery atherosclerosis complicated by acute plaque rupture, fissuring, or erosion. Rare causes include coronary artery vasospasm (Prinzmetal angina), spontaneous coronary artery dissection (SCAD), or coronary embolism.

Primary Causes

Atherosclerotic plaque rupture with thrombosis

Coronary artery spasm

Coronary artery dissection

Demand ischemia (severe anemia, tachycardia)

• Hypertension: Causes endothelial dysfunction and accelerates plaque formation.
• Dyslipidemia: High LDL cholesterol deposits into the arterial intima, forming atheromas.
• Tobacco smoking: Promotes a pro-thrombotic state and vasoconstriction.
• Diabetes Mellitus: Considered a coronary heart disease risk equivalent; causes widespread diffuse vascular damage.

An atherosclerotic plaque with a large lipid core and a thin fibrous cap becomes inflamed. Macrophages secrete metalloproteinases that degrade the fibrous cap, leading to its rupture. Highly thrombogenic core materials (tissue factor, collagen) are exposed to circulating blood. Platelets immediately adhere, activate, and aggregate (white thrombus). The coagulation cascade is activated, generating thrombin, which converts fibrinogen to a fibrin network that entraps red blood cells (red thrombus). This thrombus rapidly obstructs the coronary lumen. Within 20-30 minutes of total occlusion, irreversible ischemic necrosis of myocardial cells begins, spreading from the subendocardium to the epicardium.

Characteristic Clinical Presentation

• Chest pain (Angina): Crushing, squeezing, or heavy retrosternal pressure radiating to the left arm, neck, or jaw, lasting >20 minutes.
• Dyspnea: Shortness of breath due to sudden left ventricular dysfunction and pulmonary congestion.
• Diaphoresis: Profound, unexplained cold sweating driven by sympathetic nervous system activation.
• Nausea/Vomiting: More common in inferior MI due to vagal stimulation.

Physical Examination Signs

• Tachycardia or bradycardia (inferior MI with AV block)
• S4 gallop (due to stiff, ischemic left ventricle)
• New onset mitral regurgitation murmur (papillary muscle dysfunction)
• Hypotension and cool extremities (signs of cardiogenic shock)

• Ventricular Fibrillation: Fatal arrhythmia accounting for most out-of-hospital sudden cardiac deaths during an MI.
• Cardiogenic Shock: Severe pump failure resulting in inadequate systemic tissue perfusion.
• Ventricular Free Wall Rupture: Occurs 3-14 days post-MI, causing rapid cardiac tamponade and electromechanical dissociation (PEA).

Diagnostic Criteria & Guidelines

Diagnosis requires the presence of acute myocardial injury detected by abnormal cardiac biomarkers (High-Sensitivity Troponin > 99th percentile) in the setting of evidence of acute myocardial ischemia (symptoms of ischemia, new ischemic ECG changes like ST elevation/depression, or new wall motion abnormality on imaging).

Differential Diagnosis

• Aortic Dissection
• Pulmonary Embolism
• Acute Pericarditis
• Gastroesophageal Reflux (GERD) / Esophageal Spasm

Laboratory Tests & Biomarkers

• High-Sensitivity Cardiac Troponin T/I: Elevated above 99th percentile upper reference limit, with a rising/falling pattern
• CK-MB: Elevated, peaks at 24 hours, normalizes by 48-72 hrs (useful for detecting re-infarction)

Imaging Modalities & Findings

• 12-Lead Electrocardiogram (ECG): STEMI: >1mm ST elevation in 2 contiguous leads. NSTEMI/UA: ST depression or T-wave inversion.
• Echocardiogram: Regional wall motion abnormalities (hypokinesis or akinesis) corresponding to the infarcted territory.

• Unstable Angina
  Ischemic pain at rest or worsening, without elevation in cardiac biomarkers.
• NSTEMI
  Partial occlusion causing subendocardial necrosis; positive biomarkers (Troponin), no ST elevation.
• STEMI
  Total occlusion causing transmural necrosis; positive biomarkers and ST elevation on ECG.

Second-Line & Adjunctive Therapy

If PCI is unavailable within 120 minutes for STEMI: IV Thrombolytics (Tenecteplase/TNKase 30-50 mg IV push based on weight). For NSTEMI/UA: Early invasive strategy (angiogram within 24 hours) vs ischemia-guided strategy depending on risk scores (TIMI/GRACE).

Surgical & Procedural Management

Coronary Artery Bypass Grafting (CABG) is indicated for left main coronary artery disease, severe 3-vessel disease, or in diabetic patients with multivessel disease.

Recommended Lifestyle Changes

• Complete cessation of smoking and tobacco products.
• Adopt a Mediterranean or DASH diet (low in saturated fats, high in fiber and omega-3s).
• Engage in cardiac rehabilitation program for supervised, progressive aerobic exercise.

Patient Counseling & Advice

Stress the absolute necessity of taking dual antiplatelet therapy exactly as prescribed to prevent potentially fatal stent thrombosis. Educate on the use of sublingual nitroglycerin for future chest pain and to call 911 if pain is unrelieved by 1 dose after 5 minutes.

Follow-Up & Monitoring Schedule

Follow-up with cardiology within 1-2 weeks post-discharge. Repeat echocardiogram in 4-12 weeks to assess recovery of Left Ventricular Ejection Fraction (LVEF). Routine monitoring of lipid panel to ensure LDL < 55 mg/dL on statin therapy.

Preventive Strategies

Primary: Aggressive management of hypertension, diabetes, and hyperlipidemia. Secondary: Lifelong Aspirin 81 mg, a P2Y12 inhibitor for 12 months, Beta-blocker (e.g., Metoprolol succinate 50 mg daily), ACE inhibitor/ARB (e.g., Lisinopril 10 mg daily), and a high-intensity statin.

In-hospital mortality for STEMI treated with primary PCI is ~5%. Prognosis heavily depends on the extent of myocardial damage, post-MI ejection fraction, and age. Post-MI heart failure significantly reduces long-term survival.